217 related articles for article (PubMed ID: 34145336)
1. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
Ueno M; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ikeda M; Ozaka M; Okano N; Sugimori K; Todaka A; Shimizu S; Mizuno N; Yamamoto T; Sano K; Tobimatsu K; Katanuma A; Miyamoto A; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Miyakawa H; Yamashita T; Yasuda I; Takahashi H; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Sci Rep; 2021 Jun; 11(1):12885. PubMed ID: 34145336
[TBL] [Abstract][Full Text] [Related]
2. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
4. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Yamada I; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ueno M; Ikeda M; Okano N; Todaka A; Shimizu S; Mizuno N; Sekimoto M; Tobimatsu K; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Okamura K; Yamashita T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Sci Rep; 2022 Jan; 12(1):987. PubMed ID: 35046457
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
Williams KJ; Picus J; Trinkhaus K; Fournier CC; Suresh R; James JS; Tan BR
HPB (Oxford); 2010 Aug; 12(6):418-26. PubMed ID: 20662793
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
[TBL] [Abstract][Full Text] [Related]
9. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
10. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
13. Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery.
Kato A; Shimizu H; Ohtsuka M; Yoshitomi H; Furukawa K; Takayashiki T; Nakadai E; Kishimoto T; Nakatani Y; Yoshidome H; Miyazaki M
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1093-9. PubMed ID: 26240009
[TBL] [Abstract][Full Text] [Related]
14. Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.
Fukutomi A; Furuse J; Okusaka T; Miyazaki M; Taketsuna M; Koshiji M; Nimura Y
HPB (Oxford); 2012 Apr; 14(4):221-7. PubMed ID: 22404259
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Moehler M; Maderer A; Ehrlich A; Foerster F; Schad A; Nickolay T; Ruckes C; Weinmann A; Sivanathan V; Marquardt JU; Galle PR; Woerns M; Thomaidis T
BMC Cancer; 2019 Jan; 19(1):55. PubMed ID: 30634942
[TBL] [Abstract][Full Text] [Related]
18. Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113.
Okano N; Morizane C; Okusaka T; Sadachi R; Kataoka T; Kobayashi S; Ikeda M; Ozaka M; Mizutani T; Sugimori K; Todaka A; Shimizu S; Mizuno N; Yamamoto T; Sano K; Tobimatsu K; Katanuma A; Gotoh K; Yamaguchi H; Ishii H; Ohba A; Furuse J; Ueno M;
Oncologist; 2024 Jan; 29(1):e97-e107. PubMed ID: 37531645
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
